V InterAmerican Oncology Conference: Current Status and Future of Anti-Cancer Targeted Therapies

InterAmerican Oncology Conferences
Last Modified: January 23, 2013

Dates: October 10-11, 2013
Location: Universidad Católica Argentina, Alicia M. de Justo 1680, Puerto Madero. Buenos Aires, Argentina

Sponsoring Group: InterAmerican Oncology Conferences

Web Page URL: www.oncologyconferences.com.ar

Topics Covered: The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.

Objectives: The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development.

Who Should Attend: This meeting is the primary opportunity for hematologist, practicing oncologists, basic and clinical, scientists, translational investigators and health care workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care.

Agenda: The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types.

Registration Information:

Fees: The conference does not charge a registration fee

Continuing Education: No

Audience: HCP

Blogs

Is Ayurveda the Answer to Women’s Health Issues?
by The 4Wholeness Team
September 01, 2015

Related News

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

Aug 16, 2015

RAD51C and RAD51D deleterious mutations linked to increased risk of epithelial ovarian cancer


AACR: Conference Offers Look at Cancer Drugs in Pipeline

Sep 3, 2015

International conference presentations include leukemia drug screening, olaparib, cediranib


But does not completely offset risk conferred by family history of late-onset breast cancer

Oct 14, 2010

But does not completely offset risk conferred by family history of late-onset breast cancer